FDA Approved Products

4,491 products with lifecycle intelligence, competitive pressure scores, and patent timelines.

Type:AllNDABLAANDA
Lifecycle:GrowthPeakLOE ApproachingPost-LOELaunchPre-Launch
Sort:Approval DateNameCompetitive Pressure↓
Active:Lifecycle: LOE ApproachingClear all
CORTEF ACETATE
hydrocortisone acetate
LOE Approaching
Pfizer
TOPICAL · OINTMENT
1953
NDA
30/100
CORTENEMA
hydrocortisone
LOE Approaching
ANI Pharmaceuticals
RECTAL · ENEMA
ulcerative colitis
1966
NDA
30/100
CORTICOTROPIN
corticotropin
LOE Approaching
INJECTION · INJECTABLE
the following disorders: 1Rheumatoid arthritis+3
1957
NDA
30/100
CORTIFOAM
hydrocortisone acetate
LOE Approaching
Viatris (2)
RECTAL · AEROSOL, METERED
1982
NDA
30/100
CORTISONE ACETATE
cortisone acetate
LOE Approaching
ORAL · TABLET
stressfatigue+1
1952
NDA
30/100
CORTISONE ACETATE
cortisone acetate
LOE Approaching
ORAL · TABLET
stressfatigue+1
2001
NDA
30/100
CORTISONE ACETATE
cortisone acetate
LOE Approaching
Pfizer
ORAL · TABLET
stressfatigue+1
1951
NDA
30/100
CORTISPORIN
bacitracin zinc; hydrocortisone; neomycin sulfate; polymyxin b sulfate
LOE Approaching
R-Pharm US
OPHTHALMIC · OINTMENT
superficial bacterial infections of the external auditory canalcaused by organisms susceptible to the action of the antibiotics
1971
NDA
30/100
CORTISPORIN
hydrocortisone; neomycin sulfate; polymyxin b sulfate
LOE Approaching
Monarch Therapeutics
OPHTHALMIC · SUSPENSION/DROPS
superficial bacterial infections of the external auditory canalcaused by organisms susceptible to the action of the antibiotics
1964
NDA
30/100
CORTISPORIN
bacitracin zinc; hydrocortisone; neomycin sulfate; polymyxin b sulfate
LOE Approaching
Monarch Therapeutics
TOPICAL · OINTMENT
superficial bacterial infections of the external auditory canalcaused by organisms susceptible to the action of the antibiotics
1957
NDA
30/100
CORTISPORIN
hydrocortisone; neomycin sulfate; polymyxin b sulfate
LOE Approaching
Monarch Therapeutics
OTIC · SOLUTION/DROPS
superficial bacterial infections of the external auditory canalcaused by organisms susceptible to the action of the antibiotics
1975
NDA
30/100
CORTISPORIN
hydrocortisone acetate; neomycin sulfate; polymyxin b sulfate
LOE Approaching
Monarch Therapeutics
TOPICAL · CREAM
superficial bacterial infections of the external auditory canalcaused by organisms susceptible to the action of the antibiotics
1963
NDA
30/100
CORTONE
cortisone acetate
LOE Approaching
Merck & Co.
INJECTION · INJECTABLE
stressfatigue+1
1950
NDA
30/100
CORTONE
cortisone acetate
LOE Approaching
Merck & Co.
ORAL · TABLET
stressfatigue+1
1950
NDA
30/100
CORTRIL
hydrocortisone
LOE Approaching
Pfizer
TOPICAL · OINTMENT
1972
NDA
30/100
CORTRIL
hydrocortisone
LOE Approaching
Pfizer
ORAL · TABLET
1953
NDA
30/100
CORTROPHIN-ZINC
corticotropin-zinc hydroxide
LOE Approaching
ANI Pharmaceuticals
INJECTION · INJECTABLE
1955
NDA
30/100
CORTROSYN
cosyntropin
LOE Approaching
R-Pharm US
INJECTION · INJECTABLE
1970
NDA
30/100
CORVERT
ibutilide fumarate
LOE Approaching
Pfizer
INJECTION · INJECTABLE
atrial fibrillation
1995
NDA
30/100
CORZIDE
bendroflumethiazide; nadolol
LOE Approaching
Pfizer
ORAL · TABLET
hypertensionto lower blood pressure+1
1983
SMNDA
30/100
COSMEGEN
dactinomycin
LOE Approaching
Recordati
INJECTION · INJECTABLE
part of a multi-phasecombination chemotherapy regimen+7
1964
NDA
30/100
COSOPT
dorzolamide hydrochloride and timolol maleate
LOE Approaching
Thea Pharma
OPHTHALMIC · SOLUTION/DROPS
elevated intraocular pressure (IOP) in patients with open-angle glaucomaocular hypertension+2
1998
NDA
30/100
COSYNTROPIN
cosyntropin
LOE Approaching
Novartis
INTRAVENOUS · SOLUTION
2008
NDA
30/100
COUMADIN
warfarin sodium
LOE Approaching
Bristol Myers Squibb
ORAL · TABLET
pulmonary embolismatrial fibrillation+3
1954
NDA
30/100
← PreviousPage 37 of 188Next →